ECSP055855A - Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato - Google Patents

Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato

Info

Publication number
ECSP055855A
ECSP055855A EC2005005855A ECSP055855A ECSP055855A EC SP055855 A ECSP055855 A EC SP055855A EC 2005005855 A EC2005005855 A EC 2005005855A EC SP055855 A ECSP055855 A EC SP055855A EC SP055855 A ECSP055855 A EC SP055855A
Authority
EC
Ecuador
Prior art keywords
salt
tiotropio
salmeterolxinafoato
drugs containing
inhalation powder
Prior art date
Application number
EC2005005855A
Other languages
English (en)
Inventor
Michael Trunk
Peter Sieger
Mareke Hartig
Michael Walz
Hagen Graebner
Rainer Soyka
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP055855A publication Critical patent/ECSP055855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a preparaciones en polvo para inhalación que contienen una sal de tiotropio y salmeterolxinafoato, a procedimientos para su preparación, así como a su uso para la preparación de un medicamento para el tratamiento de enfermedades de las vías respiratorias, en especial para el tratamiento de EPOC (= enfermedad pulmonar obstructiva crónica) y asma
EC2005005855A 2002-12-20 2005-06-15 Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato ECSP055855A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20

Publications (1)

Publication Number Publication Date
ECSP055855A true ECSP055855A (es) 2005-11-22

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005855A ECSP055855A (es) 2002-12-20 2005-06-15 Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato

Country Status (21)

Country Link
EP (1) EP1581198A1 (es)
JP (1) JP2006516135A (es)
KR (1) KR20050086930A (es)
CN (1) CN1728988B (es)
AU (1) AU2003288226B2 (es)
BR (1) BR0317443A (es)
CA (1) CA2510779A1 (es)
DE (1) DE10351663A1 (es)
EA (1) EA010588B1 (es)
EC (1) ECSP055855A (es)
FR (1) FR2848849B1 (es)
HR (1) HRP20050570A2 (es)
IT (1) ITMI20032473A1 (es)
MX (1) MXPA05006519A (es)
NO (1) NO20053548L (es)
NZ (1) NZ541303A (es)
PL (1) PL376231A1 (es)
RS (1) RS20050484A (es)
UA (1) UA83813C2 (es)
WO (1) WO2004058233A1 (es)
ZA (1) ZA200503692B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
WO2007017437A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
US8163913B2 (en) 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
DE102007036411A1 (de) * 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
BR112021009254A2 (pt) * 2018-11-13 2021-08-10 Cocrystal Pharma, Inc. formulações para produtos terapêuticos para influenza

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE10104367A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
EP1416990A1 (en) * 2001-08-09 2004-05-12 Glaxo Group Limited Inhalation device with a pharmaceutical composition
JP2005504076A (ja) * 2001-09-14 2005-02-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な吸入用医薬組成物

Also Published As

Publication number Publication date
AU2003288226A1 (en) 2004-07-22
AU2003288226B2 (en) 2010-01-07
KR20050086930A (ko) 2005-08-30
CN1728988A (zh) 2006-02-01
PL376231A1 (en) 2005-12-27
CA2510779A1 (en) 2004-07-15
BR0317443A (pt) 2005-11-16
ITMI20032473A1 (it) 2004-06-21
UA83813C2 (ru) 2008-08-26
HRP20050570A2 (en) 2006-07-31
MXPA05006519A (es) 2005-08-26
EP1581198A1 (de) 2005-10-05
EA010588B1 (ru) 2008-10-30
NZ541303A (en) 2008-11-28
WO2004058233A1 (de) 2004-07-15
JP2006516135A (ja) 2006-06-22
CN1728988B (zh) 2010-04-28
DE10351663A1 (de) 2004-07-01
EA200500902A1 (ru) 2006-02-24
ZA200503692B (en) 2006-10-25
FR2848849A1 (fr) 2004-06-25
NO20053548L (no) 2005-09-02
RS20050484A (sr) 2007-11-15
FR2848849B1 (fr) 2007-01-05

Similar Documents

Publication Publication Date Title
ECSP055855A (es) Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato
ECSP024268A (es) Nuevos polvos para inhalacion que contienen tiotropio
UY31235A1 (es) Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
MEP30108A (en) Formoterol superfine formulation
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
UY28589A1 (es) Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen
CY1114157T1 (el) Αλατα του τιοτροπιου, μεθοδος για την παραγωγη τους και φαρμακευτικα σκευασματα που τα περιεχουν
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
NO20051956L (no) Salmeterol superfin formulering
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
EA201201391A1 (ru) Ингалятор
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
RU2010120806A (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
DE60308497D1 (de) Pulverzubereitungen zur inhalation